title: TAp73 is required for macrophage-mediated innate immunity and the resolution of inflammatory responses.
abstract: The multiple isoforms of p73, a member of the p53 family, share the ability to modulate p53 activities but also have unique properties, leading to a complex and poorly understood functional network. In vivo, p73 isoforms have been implicated in tumor suppression (TAp73(-/-) mice), DNA damage (ΔNp73(-/-) mice) and development (p73(-/-) mice). In this study, we investigated whether TAp73 contributes to innate immunity and septic shock. In response to a lethal lipopolysaccharide (LPS) challenge, TAp73(-/-) mice showed higher blood levels of proinflammatory cytokines and greater mortality than their wild-type littermates. In vitro, TAp73(-/-) macrophages exhibited elevated production of tumor necrosis factor alpha , interleukin-6 and macrophage inflammatory protein-2 as well as prolonged survival, decreased phagocytosis and increased major histocompatibility complex class II expression. Mice depleted of endogenous macrophages and reconstituted with TAp73(-/-) macrophages showed increased sensitivity to LPS challenge. These results suggest that macrophage polarization is altered in the absence of TAp73 such that maintenance of the M1 effector phenotype is prolonged at the expense of the M2 phenotype, thus impairing resolution of the inflammatory response. Our data indicate that TAp73 has a role in macrophage polarization and innate immunity, enhancing the action field of this important regulatory molecule.
authors.affiliation: INSERM U1068, CRCM, Stress Cellulaire, 163 Avenue de Luminy, Case 915, Parc de Luminy, 13288 Marseille Cedex 9, France. richard.tomasini@inserm.fr
authors.forename: R
authors.initials: R
authors.lastname: Tomasini
authors.forename: V
authors.initials: V
authors.lastname: Secq
authors.forename: L
authors.initials: L
authors.lastname: Pouyet
authors.forename: A K
authors.initials: AK
authors.lastname: Thakur
authors.forename: M
authors.initials: M
authors.lastname: Wilhelm
authors.forename: J
authors.initials: J
authors.lastname: Nigri
authors.forename: S
authors.initials: S
authors.lastname: Vasseur
authors.forename: P
authors.initials: P
authors.lastname: Berthezene
authors.forename: E
authors.initials: E
authors.lastname: Calvo
authors.forename: G
authors.initials: G
authors.lastname: Melino
authors.forename: T W
authors.initials: TW
authors.lastname: Mak
authors.forename: J L
authors.initials: JL
authors.lastname: Iovanna
mesh_terms: D000818:Animals; D002478:Cells, Cultured; D054426:Chemokine CXCL2 / Q000378:metabolism; D004268:DNA-Binding Proteins / Q000172:deficiency / Q000235:genetics / Q000378:metabolism*; D005786:Gene Expression Regulation / Q000187:drug effects; D007113:Immunity, Innate; D016899:Interferon-beta / Q000378:metabolism; D015850:Interleukin-6 / Q000378:metabolism; D008070:Lipopolysaccharides / Q000633:toxicity; D008264:Macrophages / Q000187:drug effects / Q000276:immunology / Q000378:metabolism*; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D018345:Mice, Knockout; D009687:Nuclear Proteins / Q000172:deficiency / Q000235:genetics / Q000378:metabolism*; D010641:Phenotype; D020033:Protein Isoforms / Q000172:deficiency / Q000235:genetics / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism; D000072160:Tumor Protein p73; D025521:Tumor Suppressor Proteins / Q000172:deficiency / Q000235:genetics / Q000378:metabolism*
chemical_list: D054426:Chemokine CXCL2; D004268:DNA-Binding Proteins; D015850:Interleukin-6; D008070:Lipopolysaccharides; D009687:Nuclear Proteins; D020033:Protein Isoforms; C000606368:Trp73 protein, mouse; D014409:Tumor Necrosis Factor-alpha; D000072160:Tumor Protein p73; D025521:Tumor Suppressor Proteins; D016899:Interferon-beta